Category Archives: Psoriasis

Download Advances in Psoriasis PDF A Multisystemic Guide
Download Link : http://bit.ly/1P1u6wy Login to the website and feel free to download the PDF. Please register first if you don #39;t have an account.

By: Anjani Lerkipari

Continued here:
Download Advances in Psoriasis PDF A Multisystemic Guide - Video

Home Made Hair Oil For Dandruff Scalp Psoriasis
SUBSCRIBE OUR CHANNEL FOR REGULAR UPDATES: http://www.youtube.com/subscription_center?add_user=f3healthcare Like us on Facebook: http://www.facebook.com/F3HealthCare Join our ...

By: F3 Health Care - Cure yourself with Home Remedies

See original here:
Home Made Hair Oil For Dandruff & Scalp Psoriasis - Video

PBR Staff Writer Published 02 April 2015

The European Commission (EC) has granted marketing authorization for AbbVie's Humira (adalimumab) to treat children and adolescents with severe chronic plaque psoriasis.

The drug is indicated for use in children and adolescents from four years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

With the latest approval, Humira is now marketed for use in this indication in all member states of the European Union (EU).

The approval is based on the positive results of a Phase III trial, which will be reported at an upcoming medical meeting.

Currently, Humira has been approved in more than 87 countries and is being used to treat more than 851,083 patients worldwide.

AbbVie Research and Development executive vice president and chief scientific officer Michael Severino said: "With the approval from the European Commission, Humira is now the only biologic approved in Europe to treat children with this condition starting at four years of age, offering an important new option for physicians treating pediatric plaque psoriasis.

"This new indication contributes to the increasingly broad spectrum of indications for Humira, and supports its strong record of efficacy and safety in treating pediatric populations who are managing challenging chronic diseases."

Humira is indicated to treat severe rheumatoid arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis, active and progressive psoriatic arthritis, moderate to severely active Crohn's disease and moderate to severely active ulcerative colitis.

See the rest here:
AbbVie's plaque psoriasis drug Humira gets marketing approval in Europe

New Medication Shows Early Promise for Psoriasis Patients
The development of new medications to help patients with plaque psoriasis seems to take steps forward on a daily basis. Results presented at a recent conference showed at least one could help...

By: HCPLiveTV

See the original post:
New Medication Shows Early Promise for Psoriasis Patients - Video

Psoriasis Healing Mentorship With Matt Ludwig - Win A Free Session!
http://www.psoriasisdiary.com/mentor - click that link to register before midnight Saturday, March 28th for a chance to win a free 1on1 private mentorship program with me, Matt Ludwig! I want...

By: PHWarrior

Continue reading here:
Psoriasis Healing Mentorship With Matt Ludwig - Win A Free Session! - Video

Psoriasis and Quality of Life
For more informative videos go to: http://newsplexnow.com/

By: Newsplex Now

See the original post here:
Psoriasis and Quality of Life - Video

HUMIRA is the only Biologic Approved in Europe for Children and Adolescents from Four Years of Age with Severe Chronic Plaque Psoriasis

NORTH CHICAGO, Illinois, April 1, 2015 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has granted marketing authorization for HUMIRA (adalimumab) for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. With the EC decision, HUMIRA now has approval for use in this indication in all member states of the European Union.

"Several treatments have been shown to be effective in subgroups of patients with pediatric psoriasis. However, a limited body of supporting data is available. The approval of adalimumab is an important milestone in particular for children with severe disease because it extends the armamentarium of the physicians who are working to reduce the burden of this chronic disease in this sensitive young patient population," said Marieke M.B. Seyger, MD, PhD, Associate Professor of Dermatology, Radboud University Medical Center in Nijmegen, Netherlands.

The marketing authorization is based on the positive results of a Phase 3 study, which will be presented at an upcoming medical meeting. Since first gaining approval 12 years ago, HUMIRA has been approved in more than 87 countries. It is currently being used to treat more than 851,083 patients worldwide1 across 11 globally approved indications.2

"With the approval from the European Commission, HUMIRA is now the only biologic approved in Europe to treat children with this condition starting at four years of age, offering an important new option for physicians treating pediatric plaque psoriasis," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "This new indication contributes to the increasingly broad spectrum of indications for HUMIRA, and supports its strong record of efficacy and safety in treating pediatric populations who are managing challenging chronic diseases."

About Pediatric Chronic Plaque PsoriasisAccording to estimates from the World Health Organization, pediatric psoriasis occurs in 0.70 percent of the pediatric population,3 with no significant difference by gender.4 The chronic autoimmune disease is characterized by the rapid and excessive accumulation of skin cells, which form thick patches of inflamed, scaly skin.5 Pediatric psoriasis has similar characteristics to adult psoriasis, but in children, the psoriatic lesions are typically smaller, thinner, and less scaly.4 Beyond the physical challenges of managing the chronic skin disorder, it is also considered to have significant emotional and psychological effects.6

HUMIRA EU Therapeutic Indications2HUMIRA is approved for use in moderate to severe rheumatoid arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis, active and progressive psoriatic arthritis, moderate to severely active Crohn's Disease and moderate to severely active ulcerative colitis.HUMIRA is approved in pediatric patients for use in enthesitis-related arthritis, severe plaque psoriasis, severe Crohn's disease, and active juvenile idiopathic arthritis in patients who have had inadequate response to prior therapy. See SmPC for full indication.

Important EU Safety Information2 HUMIRA is contraindicated in patients with active tuberculosis or other severe infections and in patients with moderate to severe heart failure. The use of HUMIRA increases the risk of developing serious infections which may, in rare cases, be life-threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with a TNF-antagonist. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache, abdominal pain, nausea, rash and musculoskeletal pain.

(see SmPC for full details at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp&mid=WC0b01ac058001d124)

About AbbVieAbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit http://www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Link:
AbbVie's HUMIRA (Adalimumab) Approved by European Commission to Treat Children and Adolescents with Severe Chronic ...

Juckatan Jucka Tan Juckreiz Dialyse Psoriasis Neurodermitis Tipps
Juckreiz : Jucka-Tan ( Juckatan) Juckreiz ( Pruritus ) lst das Verlangen nach Kratzen, Reiben oder Scheuern aus. Er tritt hufig bei Stoffwechselstrungen wie Dialyse und Diabetes oder...

By: sivenov peyo

See original here:
Juckatan Jucka Tan Juckreiz Dialyse Psoriasis Neurodermitis Tipps - Video

How To Treat Eczema and Psoriasis Naturally VitaLife Show Episode 180
How To Treat Eczema and Psoriasis Naturally In this episode of the VitaLife Show, Dr. Janine Bowring, ND, expains the importance of treating eczema naturally from the inside out. She answers...

By: VitaTree VitaLife Show

Originally posted here:
How To Treat Eczema and Psoriasis Naturally VitaLife Show Episode 180 - Video

Treatment of Plaque Psoriasis Taking Big Steps Forward
The armament of medications and treatments for plaque psoriasis and psoriatic arthritis continues to grow giving doctors and patients more choices for their treatment options.

By: HCPLiveTV

Read more from the original source:
Treatment of Plaque Psoriasis Taking Big Steps Forward - Video